$1.69
1.17% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US45175G1085
Symbol
IKNA
Sector
Industry

Ikena Oncology Inc Stock price

$1.69
-0.02 1.17% 1M
+0.36 26.59% 6M
-0.28 14.21% YTD
+0.29 20.71% 1Y
-14.51 89.57% 3Y
-14.31 89.44% 5Y
-14.31 89.44% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.02 1.17%
ISIN
US45175G1085
Symbol
IKNA
Sector
Industry

Key metrics

Market capitalization $81.56m
Enterprise Value $-48.08m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.78
EV/Sales (TTM) EV/Sales -72.85
P/S ratio (TTM) P/S ratio 123.58
P/B ratio (TTM) P/B ratio 0.61
Revenue growth (TTM) Revenue growth -95.28%
Revenue (TTM) Revenue $660.00k
EBIT (operating result TTM) EBIT $-64.29m
Free Cash Flow (TTM) Free Cash Flow $-61.83m
Cash position $138.03m
EPS (TTM) EPS $-1.24
P/E forward negative
Short interest 0.34%
Show more

Is Ikena Oncology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Ikena Oncology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Ikena Oncology Inc forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Ikena Oncology Inc forecast:

Buy
67%
Hold
33%

Financial data from Ikena Oncology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.66 0.66
95% 95%
100%
- Direct Costs 0.71 0.71
60% 60%
108%
-0.05 -0.05
100% 100%
-8%
- Selling and Administrative Expenses 24 24
24% 24%
3,586%
- Research and Development Expense 40 40
33% 33%
6,039%
-64 -64
5% 5%
-9,633%
- Depreciation and Amortization 0.71 0.71
60% 60%
108%
EBIT (Operating Income) EBIT -64 -64
6% 6%
-9,740%
Net Profit -60 -60
5% 5%
-9,030%

In millions USD.

Don't miss a Thing! We will send you all news about Ikena Oncology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ikena Oncology Inc Stock News

Neutral
GlobeNewsWire
9 days ago
Strong financial position with $138 million in cash and investments at close of third quarter Strong financial position with $138 million in cash and investments at close of third quarter
Neutral
GlobeNewsWire
3 months ago
Strong financial position with $145 million in cash and investments at close of second quarter Strong financial position with $145 million in cash and investments at close of second quarter
Neutral
GlobeNewsWire
6 months ago
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK...
More Ikena Oncology Inc News

Company Profile

Ikena Oncology, Inc. is a clinical stage biotechnology company. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.

Head office United States
CEO Mark Manfredi
Employees 43
Founded 2016
Website www.ikenaoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today